Buy 3 and get the 4th FREE!* | Learn More >>
12739
Human IL-17A Neutralizing (D13C2) Rabbit mAb
Primary Antibodies

Human IL-17A Neutralizing (D13C2) Rabbit mAb #12739

Reviews ()
Citations (0)

The ability of Human IL-17A Neutralizing (D13C2) Rabbit mAb to inhibit IL-17A-induced IL-6 production was assessed. Human dermal fibroblasts were incubated with increasing concentrations of antibody in the presence of Human Interleukin-17A (hIL-17A) #8928 (15 ng/ml). After 48 hr, culture supernatants were harvested and assayed for IL-6 by ELISA and the OD450 was determined.

The production of IL-6 by human dermal fibroblasts cultured with increasing concentrations of Human IL-17A (hIL-17A) #8928 was assessed. Media from cells incubated with IL-17A for 48 hours was collected and assayed for IL-6 by ELISA and the OD450 was determined.

To Purchase # 12739S
Product # Size Price
12739S
100 µg $ 345

Supporting Data

REACTIVITY H
SENSITIVITY
MW (kDa)
Isotype Rabbit IgG

Product Description

Neutralizing antibodies can be used to inhibit normal biological function through their binding to biological molecules. These reagents can be used to determine the effects that a particular molecule has in biological systems. Human IL-17A Neutralizing (D13C2) Rabbit mAb has been shown to neutralize the production of IL-6 from human dermal fibroblast cells in vitro with an ND50 in the range of 8-50 ng/ml.

Endotoxin:

Less than 0.1 EU/µg of antibody

Product Usage Information

CST recommends incubation of the neutralizing antibody with the intended target for 1 hr at 37ºC before addition to the experiment at an optimal concentration determined by the user.

Application Dilutions
Neutralizing 1:1

Formulation:

Lyophilized from a 0.2 µm filtered solution in 10 mM HEPES with trehalose.

Storage:

Store lyophilized material at -20ºC. After reconstitution, recommended storage at 4ºC for 1 month or -20ºC for 6 months. Avoid repeated freeze/thawing.

Specificity / Sensitivity

Human IL-17A Neutralizing (D13C2) Rabbit mAb binds to human IL-17A (hIL-17A) and neutralizes its ability to induce IL-6 production in human dermal fibroblast cells. This antibody shows 50% cross-reactivity with human IL-17A/F. This antibody does not cross-react with mouse IL-17A, human IL-25 or mouse IL-25 .

Species Reactivity:

Human

Source / Purification

Monoclonal antibody is produced by immunizing animals with a recombinant human IL-17A protein.

Background

IL-17A is a cystine-linked homodimeric pro-inflammatory cytokine produced by Th17 cells, a distinct CD4+ T cell lineage (1,2). IL-17A stimulates the production of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6. IL-17A also induces production of the neutrophil chemoattractants IL-8, CXCL1, and CXCL6 thereby bridging adaptive and innate immunity (1,2). IL-17A is intimately involved in mucosal immunity against bacterial infections (1,3) and has a putative role in some autoimmune disorders (1,4). IL-17A effects appear to be exerted primarily through binding to the IL-17RA (5). IL-17A binding induces production of cytokines, chemokines and other proteins through activation of the Erk1/2 MAP kinase, PI3K/Akt, p38, and NF-κB pathways (3,4,6).

  1. Kolls, J.K. and Lindén, A. (2004) Immunity 21, 467-76.
  2. Liang, S.C. et al. (2006) J Exp Med 203, 2271-9.
  3. Wright, J.F. et al. (2008) J Immunol 181, 2799-805.
  4. Dubin, P.J. and Kolls, J.K. (2008) Immunol Rev 226, 160-71.
  5. Zrioual, S. et al. (2009) J Immunol 182, 3112-20.
  6. Rahman, M.S. et al. (2006) J Immunol 177, 4064-71.

Pathways & Proteins

Explore pathways + proteins related to this product.

For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.